JPH0351691B2 - - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a therapeutic agent for renal nephrosis containing pronase as an active ingredient.

[Prior Art] Kidney diseases are already well known.
As is well known, nephritis, the most common kidney disease, is divided into acute nephritis and chronic nephritis, and as the symptoms of chronic nephritis progress further, the disease progresses to renal nephrosis (nephrotic syndrome) and then to renal failure.

Acute nephritis is a sudden and temporary inflammation of the kidney tissue due to various causes, especially bacterial causes, and is usually treated with antibiotics, and may resolve spontaneously.

On the other hand, in chronic nephritis, unlike acute nephritis, which is a temporary inflammation of the kidney tissue, the kidney tissue undergoes irreversible changes such as hyalinization of the glomeruli, proliferation of fibrillated tissue, narrowing of blood vessels, and degeneration of the nephron. , kidney atrophy,
There is a significant decrease in red blood cells and white blood cells, and this is not considered to be tissue inflammation.

As described above, acute nephritis and chronic nephritis are completely different in their pathological features and histological changes, and different treatment methods are used for each of these diseases. More specifically, for acute nephritis, the cause of the inflammation is treated by administering antibiotics, but for chronic nephritis, there is currently no active treatment, and symptomatic treatment is currently being taken.

[Problems to be Solved by the Invention] Therefore, if the inflammation during the stage of acute nephritis is cured, it is thought that the transition to chronic nephritis can be significantly suppressed, but once the transition to chronic nephritis such as chronic glomerulonephritis occurs. Once this occurs, it is no longer possible to take the same therapeutic measures as those for acute nephritis, and it was thought that there was no active measure to cure chronic nephritis or to stop the progression to renal nephrosis and then renal dysfunction.

[Means for Solving the Problems] As a result of many years of research into proteolytic enzymes, the present inventors found that pronase, a proteolytic enzyme, is surprisingly effective not only for chronic nephritis but also for renal nephrosis treatment. We have discovered a completely new fact that it is highly effective in treatment, and have completed the present invention.

Please note that the original application for this application (Japanese Patent Application No. 125002/1982:
Chronic nephritis as used in the invention described in Japanese Patent Publication No. 1-33085) refers to nephritis in which the amount of proteinuria excreted is less than 3.5 g/day, while renal nephrosis as referred to in the present invention refers to nephritis in which the amount of proteinuria excreted is less than 3.5 g/day. / days or more.

[Operations and Examples] The therapeutic agent of the present invention can be administered orally in the form of tablets, capsules, powders, granules, etc., or parenterally as injections, suppositories, ointments, etc., using conventional manufacturing techniques. . Furthermore, this drug can be used in combination with other drugs, such as liver drugs, kidney drugs, antibiotics, immunostimulants, and antitumor drugs. The dosage varies depending on the degree of disease, administration method, dosage form, etc., but in the case of oral administration,
The objective can be achieved with 1 to 50,000 mg per person per day, and as an enteric-coated preparation, with 1 to 1,000 mg. When the dosage is expressed in enzyme units, the purpose can be achieved by oral administration of 10,000 to 500,000 tyrosine units in an enteric preparation. In particular, enteric-coated preparations are preferred.

The therapeutic agent of the present invention is characterized by a very large amount of absorbed pronase being transferred to the kidney at the site of injury, and in the tissue at the site of injury, there is disappearance of edema, infiltration of round cells, new blood vessels, and dissolution of fibrin. An increase in polysaccharides, particularly acidic polysaccharides, was observed, and it was observed that a curative reaction was induced and promoted in chronic inflammation of the kidney, such as degeneration and abnormal proliferation.

Formulation Example 1 20 g of pronase and 40 g of lactose are mixed, 10 g of hydroxypropyl methyl cellulose is added and the mixture is formed into granules, which are then evenly coated with cellulose acetate phthalate to form enteric-coated granules.

Formulation Example 2 The pronase enteric-coated granules obtained in Formulation Example 1 are filled into capsules to prepare capsules.

Clinical case Male, 48 years old Diagnosis: Nephrotic syndrome Chief complaint: Anorexia, lethargy History of present illness: The patient had been complaining of anorexia and lethargy for six months, but was left untreated. Proteinuria was noted during a medical examination.

Current symptoms: physique, moderate nutrition, facial edema.
Blood pressure: 163/92 Urinalysis: Shows a large amount of proteinuria of 3.8 g/day.

Urine sediment: Granular casts, hyaline casts, and fatty casts are observed. In particular, a heavily refractive fat pad was observed in this case.

The patient was referred to the Osaka Prefectural Adult Disease Center, and after various tests, he was diagnosed with nephrotic syndrome.

Treatment with pronase: From December 8th, the patient started taking 6 tablets of Empinase P per day, 2 tablets after each meal.

January 14th of the following year: Urine protein decreased to 2.4g/day. There was no change in the urine sediment, and all casts were detected.

February 21st: Urine protein decreased to 1.2g/day.

Urine sediment decreased overall, but casts were still observed.

March 30th: No protein in urine was detected. Urine sediment disappeared.

The disease was almost cured in about 110 days.

[Effects of the Invention] The therapeutic agent of the present invention containing pronase as an active ingredient exhibits an outstanding effect on the treatment of renal nephrosis, for which no effective drug therapy has hitherto been considered.

Claims (1)

[Claims] 1. A therapeutic agent for renal nephrosis containing pronase as an active ingredient.